Clinical Trial Update: 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks [Phase 2, Phase 3]

View source ↗

Summary

BioCryst reports results from a 12-week safety and efficacy study of BCX4161 as an oral prophylaxis for hereditary angioedema (HAE) in a combined Phase 2/3 prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BCX4161

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema, HAE | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-11-17